{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:38:24Z","timestamp":1793921904688,"version":"4.8.0"},"reference-count":34,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,5,1]]},"DOI":"10.2169\/internalmedicine.2248-23","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T22:54:16Z","timestamp":1695941656000},"page":"1185-1190","source":"Crossref","is-referenced-by-count":5,"title":["A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease"],"prefix":"10.2169","volume":"63","author":[{"given":"Michiko","family":"Yamada-Shimizu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Uchihara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ishido","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Nobusawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisei","family":"Keitoku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Takaura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Maeyashiki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10: 686-690, 2013.","DOI":"10.1038\/nrgastro.2013.171"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18: 223-238, 2021.","DOI":"10.1038\/s41575-020-00381-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Higuchi M, Tamaki N, Kurosaki M, et al. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther 55: 292-301, 2022.","DOI":"10.1111\/apt.16745"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N. Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 20: 1171-1173.e2, 2022.","DOI":"10.1016\/j.cgh.2021.07.021"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep 21: 15, 2021.","DOI":"10.1007\/s11892-021-01383-7"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77: 1797-1835, 2023.","DOI":"10.1097\/HEP.0000000000000323"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol 56: 951-963, 2021.","DOI":"10.1007\/s00535-021-01796-x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Goa KL, Barradell LB, Plosker GL. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs 52: 725-753, 1996.","DOI":"10.2165\/00003495-199652050-00008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep 22: 5, 2020.","DOI":"10.1007\/s11883-020-0823-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Morishita A, Oura K, Takuma K, et al. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int 17: 606-614, 2023.","DOI":"10.1007\/s12072-022-10453-1"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Hatanaka T, Kosone T, Saito N, et al. Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. JGH Open 5: 1183-1189, 2021.","DOI":"10.1002\/jgh3.12650"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Seko Y, Yamaguchi K, Umemura A, et al. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: a single-arm, pilot study. Hepatol Res 50: 1328-1336, 2020.","DOI":"10.1111\/hepr.13571"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sugimoto R, Iwasa M, Eguchi A, et al. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med (Lausanne) 10: 1073025, 2023.","DOI":"10.3389\/fmed.2023.1073025"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hatanaka T, Kakizaki S, Saito N, et al. Impact of pemafibrate in patients with hypertriglyceridemia and metabolic dysfunction-associated fatty liver disease pathologically diagnosed with non-alcoholic steatohepatitis: a retrospective, single-arm study. Intern Med 60: 2167-2174, 2021.","DOI":"10.2169\/internalmedicine.6574-20"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Iwadare T, Kimura T, Kunimoto H, et al. Higher responsiveness for women, high transaminase levels, and fat percentage to pemafibrate treatment for NAFLD. Biomedicines 10: 2806, 2022.","DOI":"10.3390\/biomedicines10112806"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tanaka N, Mukaiyama K, Morikawa A, et al. Pemafibrate, a novel selective PPAR\u03b1 modulator, attenuates tamoxifen-induced fatty liver disease. Clin J Gastroenterol 14: 846-851, 2021.","DOI":"10.1007\/s12328-021-01386-7"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 54: 1263-1277, 2021.","DOI":"10.1111\/apt.16596"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol 112: 18-35, 2017.","DOI":"10.1038\/ajg.2016.517"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67: 1560-1599, 2018.","DOI":"10.1002\/hep.29800"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Husain N, Blais P, Kramer J, et al. Nonalcoholic fatty liver disease (NAFLD) in the veterans administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther 40: 949-954, 2014.","DOI":"10.1111\/apt.12923"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102: 2708-2715, 2007.","DOI":"10.1111\/j.1572-0241.2007.01526.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tamaki N, Kurosaki M, Takahashi Y, et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol 36: 2960-2966, 2021.","DOI":"10.1111\/jgh.15589"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Loomba R, Sanyal AJ, Kowdley KV, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. gastroenterology 156: 88-95.e5, 2019.","DOI":"10.1053\/j.gastro.2018.09.021"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Huang DQ, Sharpton SR, Amangurbanova M, Tamaki N, Sirlin CB, Loomba R. Clinical utility of combined MRI-PDFF and ALT response in predicting histologic response in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 21: 2682-2685.e4, 2023.","DOI":"10.1016\/j.cgh.2022.08.036"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376: 1916-1922, 2010.","DOI":"10.1016\/S0140-6736(10)61272-X"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol 12: 173-184, 2018.","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Yokote K, Yamashita S, Arai H, et al. Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator (SPPARM\u03b1), in dyslipidemic patients with renal impairment. Int J Mol Sci 20: 2019.","DOI":"10.3390\/ijms20030706"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Loomba R, Ratziu V, Harrison SA. Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. Gastroenterology 162: 680-688, 2022.","DOI":"10.1053\/j.gastro.2021.10.051"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Tamaki N, Kurosaki M, Huang DQ, Loomba R. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. Hepatol Res 52: 497-507, 2022.","DOI":"10.1111\/hepr.13764"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Suzuki Y, Maekawa S, Yamashita K, et al. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease. J Gastroenterol Hepatol 38: 921-929, 2023.","DOI":"10.1111\/jgh.16154"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Tamaki N, Munaganuru N, Jung J, et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut 71: 983-990, 2022.","DOI":"10.1136\/gutjnl-2021-324264"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Tamaki N, Munaganuru N, Jung J, et al. Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD. Clin Gastroenterol Hepatol 19: 2673-2674.e3, 2021.","DOI":"10.1016\/j.cgh.2020.11.005"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol 18: 55-66, 2022.","DOI":"10.1038\/s41574-021-00584-0"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/9\/63_2248-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T03:28:54Z","timestamp":1714793334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/9\/63_2248-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2248-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"article-number":"2248-23"}}